1. Home
  2. IOVA vs SPRY Comparison

IOVA vs SPRY Comparison

Compare IOVA & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IOVA
  • SPRY
  • Stock Information
  • Founded
  • IOVA 2007
  • SPRY 2015
  • Country
  • IOVA United States
  • SPRY United States
  • Employees
  • IOVA N/A
  • SPRY N/A
  • Industry
  • IOVA Biotechnology: Biological Products (No Diagnostic Substances)
  • SPRY Biotechnology: Pharmaceutical Preparations
  • Sector
  • IOVA Health Care
  • SPRY Health Care
  • Exchange
  • IOVA Nasdaq
  • SPRY Nasdaq
  • Market Cap
  • IOVA 975.1M
  • SPRY 1.1B
  • IPO Year
  • IOVA N/A
  • SPRY N/A
  • Fundamental
  • Price
  • IOVA $2.31
  • SPRY $9.98
  • Analyst Decision
  • IOVA Buy
  • SPRY Strong Buy
  • Analyst Count
  • IOVA 11
  • SPRY 4
  • Target Price
  • IOVA $11.90
  • SPRY $31.25
  • AVG Volume (30 Days)
  • IOVA 10.3M
  • SPRY 2.4M
  • Earning Date
  • IOVA 11-06-2025
  • SPRY 11-12-2025
  • Dividend Yield
  • IOVA N/A
  • SPRY N/A
  • EPS Growth
  • IOVA N/A
  • SPRY N/A
  • EPS
  • IOVA N/A
  • SPRY N/A
  • Revenue
  • IOVA $241,525,000.00
  • SPRY $112,339,000.00
  • Revenue This Year
  • IOVA $68.14
  • SPRY N/A
  • Revenue Next Year
  • IOVA $56.64
  • SPRY $186.14
  • P/E Ratio
  • IOVA N/A
  • SPRY N/A
  • Revenue Growth
  • IOVA 636.99
  • SPRY 22367.80
  • 52 Week Low
  • IOVA $1.64
  • SPRY $9.34
  • 52 Week High
  • IOVA $12.51
  • SPRY $18.90
  • Technical
  • Relative Strength Index (RSI)
  • IOVA 53.84
  • SPRY 40.43
  • Support Level
  • IOVA $2.13
  • SPRY $9.75
  • Resistance Level
  • IOVA $2.31
  • SPRY $11.15
  • Average True Range (ATR)
  • IOVA 0.13
  • SPRY 0.64
  • MACD
  • IOVA 0.02
  • SPRY 0.06
  • Stochastic Oscillator
  • IOVA 72.97
  • SPRY 12.75

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

About SPRY ARS Pharmaceuticals Inc.

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.

Share on Social Networks: